Literature DB >> 16521861

Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing.

Patricia V Turner1, H Cheng Chen, W Michael Taylor.   

Abstract

We evaluated the pharmacokinetic profile of meloxicam (0.3 and 1.5 mg/kg) given as single and repeated (once daily for 5 d) oral doses to female rabbits (n = 5/group) to define the optimal dose and dosing interval for clinical use. Clinical signs, body weight, and serum chemistry parameters (sodium, potassium, chloride, total protein, urea, creatinine, glucose, alkaline phosphatase, gamma glutamyl transferase, and alanine aminotransferase) were evaluated before and 5 d after dosing to monitor safety at the 2 dose levels in both studies. Plasma samples were collected serially, and concentrations were determined by high performance liquid chromatography. After single oral dosing at 0.3 or 1.5 mg/kg, maximal plasma concentrations of meloxicam were achieved at 6 to 8 h and were 0.14 and 0.3 microg/ml, respectively. Plasma drug levels decreased rapidly to near-undetectable levels by 24 h. There was moderate interindividual variability in plasma meloxicam concentrations with less than proportional increases in peak plasma concentration and area under the concentration curve values at the higher dose after the single and repeat dosing. The elimination half-life was approximately 8 h at both dose levels, suggesting that metabolism was not saturated. Oral clearance of meloxicam is high in rabbits, indicating rapid metabolism and elimination. There was no accumulation of meloxicam when given at 0.3 or 1.5 mg/kg for 5 d, and meloxicam was rapidly eliminated after discontinuation of dosing. Rabbits may require a dose exceeding 0.3 mg/kg given once daily to achieve optimal plasma levels of meloxicam over a 24-h interval.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16521861

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  15 in total

1.  Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (Cynomys ludovicianus).

Authors:  Cynthia D Cary; Nicole L Lukovsky-Akhsanov; Nadia F Gallardo-Romero; Cassandram M Tansey; Sharon D Ostergaard; Willie D Taylor; Clint N Morgan; Nathaniel Powell; George W Lathrop; Christina L Hutson
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-03-01       Impact factor: 1.232

2.  Pharmacokinetics of 3 formulations of meloxicam in cynomolgus macaques (Macaca fascicularis).

Authors:  Cassondra Bauer; Patrice Frost; Stephen Kirschner
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

3.  Plasma Concentration of Meloxicam in Pediatric Rats.

Authors:  Kristina A Pugh; Kyle J Reitnauer; Robyn B Lee; William L Wilkins; John H McDonough; M Ross Pennington; Samantha R Litvin
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-11-01       Impact factor: 1.232

4.  Effects of multimodal analgesia with LowDose buprenorphine and meloxicam on fecal glucocorticoid metabolites after surgery in New Zealand white rabbits (Oryctolagus cuniculus).

Authors:  Gregg B Goldschlager; Virginia L Gillespie; Rupert Palme; Mark G Baxter
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-09       Impact factor: 1.232

5.  A Comparison of Buprenorphine, Sustained release Buprenorphine, and High concentration Buprenorphine in Male New Zealand White Rabbits.

Authors:  David D Andrews; Virginia R Fajt; Kate C Baker; Robert V Blair; Sean H Jones; Georgina L Dobek
Journal:  J Am Assoc Lab Anim Sci       Date:  2020-07-16       Impact factor: 1.232

6.  Pharmacokinetics of Sustained-release, Oral, and Subcutaneous Meloxicam over 72 Hours in Male Beagle Dogs.

Authors:  Brian J Smith; Stephen M Kirschner; Lon V Kendall
Journal:  J Am Assoc Lab Anim Sci       Date:  2020-09-02       Impact factor: 1.232

7.  Comparison of side effects between buprenorphine and meloxicam used postoperatively in Dutch belted rabbits (Oryctolagus cuniculus).

Authors:  Coreen S Cooper; Kelly A Metcalf-Pate; Christopher E Barat; Judith A Cook; Diana G Scorpio
Journal:  J Am Assoc Lab Anim Sci       Date:  2009-05       Impact factor: 1.232

8.  Are we looking in the wrong place? Implications for behavioural-based pain assessment in rabbits (Oryctolagus cuniculi) and beyond?

Authors:  Matthew C Leach; Claire A Coulter; Claire A Richardson; Paul A Flecknell
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

9.  Molecular analysis of the microbiota in hard feces from healthy rabbits (Oryctolagus cuniculus) medicated with long term oral meloxicam.

Authors:  David Eshar; J Scott Weese
Journal:  BMC Vet Res       Date:  2014-03-11       Impact factor: 2.741

10.  Evaluation of Using Behavioural Changes to Assess Post-Operative Pain in the Guinea Pig (Cavia porcellus).

Authors:  Yvette Ellen; Paul Flecknell; Matt Leach
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.